Novel Re(I) tricarbonyl coordination compounds based on 2-pyridyl-1,2,3-triazole derivatives bearing a 4-amino-substituted benzenesulfonamide arm: synthesis, crystal structure, computational studies and inhibitory activity against carbonic anhydrase I, II, and IX isoforms†

Recent advances in triazole synthesis via click chemistry and their pharmacological applications: A review

Click chemistry is a flexible method featuring only the most feasible and efficient chemical reactions. The synthesis of 1,2,3-triazole from azides and terminal acetylenes using copper(I) as a catalyst is an extremely powerful reaction due to the extreme dependability, good selectivity, and biocompatibility of the starting materials. Triazole molecules are more than simple passive linkers; through hydrogen bonding and dipole interactions, they rapidly bind with biological targets. Its applications in drug development are expanding, ranging from target-oriented in situ chemistry and combinatorial mechanisms for lead generation to bioconjugation methods to study proteins and DNA. The click chemistry has frequently been used to speed up drug discovery and optimization processes in the past few years. The click chemistry reaction based on copper-catalyzed azide-alkyne cycloaddition (CuAAC) is a biochemical process with applications in medicinal chemistry and chemical biology. Thus, click reactions are an essential component of the toolkit for medicinal chemistry and help medicinal chemists overcome the barriers in chemical reactions, increase throughput, and improve the standards of compound libraries. The review highlights the recent advancements in the copper-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry approach for synthesizing biologically important triazole moieties with a greater emphasis on synthesis methodologies and pharmacological applications. Additionally, the triazole-based FDA-approved drugs are also discussed with their mode of action to highlight the importance of the click chemistry approach in synthesizing the bioactive triazole compounds.

Chemistry of heterocycles as carbonic anhydrase inhibitors: A pathway to novel research in medicinal chemistry review

Nowadays, the scientific community has focused on dealing with different kinds of diseases by exploring the chemistry of various heterocycles as novel drugs. In this connection, medicinal chemists identified carbonic anhydrases (CA) as one of the biologically active targets for curing various diseases. The widespread distribution of these enzymes and the high degree of homology shared by the different isoforms offer substantial challenges to discovering potential drugs. Medicinal and synthetic organic chemists have been continuously involved in developing CA inhibitors. This review explored the chemistry of different heterocycles as CA inhibitors using the last 11 years of published research work. It provides a pathway for young researchers to further explore the chemistry of a variety of synthetic as well as natural heterocycles as CA inhibitors.

Electrocatalytic CO2 Reduction by [Re(CO)3Cl(3-(pyridin-2-yl)-5-phenyl-1,2,4-triazole)] and [Re(CO)3Cl(3-(2-pyridyl)-1,2,4-triazole)]

The exploration of novel electrocatalysts for CO₂ reduction is necessary to overcome global warming and the depletion of fossil fuels. In the current study, the electrocatalytic CO₂ reduction of [Re(CO)₃Cl(N-N)], where N-N represents 3-(2-pyridyl)-1,2,4-triazole (Hpy), 3-(pyridin-2-yl)-5-phenyl-l,2,4-triazole (Hph), and 2,2'-bipyridine-4,4' dicarboxylic acidic (bpy-COOH) ligands, was investigated. In CO₂-saturated electrolytes, cyclic voltammograms showed an enhancement of the current at the second reduction wave for all complexes. In the presence of triethanolamine (TEOA), the currents of Re(Hpy), Re(Hph), and Re(bpy-COOH) enhanced significantly by approximately 4-, 2-, and 5-fold at peak potentials of -1.60, -150, and -1.69 V_Ag/Ag+, respectively (in comparison to without TEOA). The reduction potential of Re(Hph) was less negative than those of Re(Hpy) and Re(COOH), which was suggested to cause its least efficiency for CO₂ reduction. Chronoamperometry measurements showed the stability of the cathodic current at the second reduction wave for at least 300 s, and Re(COOH) was the most stable in the CO₂-catalyzed reduction. The appearance and disappearance of the absorption band in the UV/vis spectra indicated the reaction of the catalyst with molecular CO₂ and its conversion to new species, which were proposed to be Re-DMF ⁺ and Re-TEOA and were supposed to react with CO₂ molecules. The CO₂ molecules were claimed to be captured and inserted into the oxygen bond of Re-TEOA, resulting in the enhancement of the CO₂ reduction efficiency. The results indicate a new way of using these complexes in electrocatalytic CO₂ reduction.

Rhenium(I) derivatives of aminoquinoline and imidazolopiperidine-based ligands: Synthesis, in vitro and in silico biological evaluation against Plasmodium falciparum

A small library of aminoquinoline and imidazolopiperidine (IMP)-based ligands, containing the 1,2,3-triazole moiety, and their corresponding tricarbonyl rhenium complexes were synthesised and their inhibitory activities evaluated against the chloroquine-sensitive (CQS) and multidrug-resistant (MDR) strains (NF54 and K1, respectively) of P. falciparum. The quinoline-based compounds (L1, L2, ReL1, and ReL2) were at least six-fold more potent than their IMP-based counterparts (L3, L4, ReL3, and ReL4) against both strains of P. falciparum, with the most promising compound (L1) displaying activity comparable to chloroquine diphosphate (CQDP) in the MDR strain. Additionally, all of the synthesised compounds have resistance indices less than CQDP. To gain insight into a possible mechanism of action, in silico hemozoin docking simulations were performed. These studies proposed that the tested compounds may act via hemozoin inhibition, as the new aminoquinoline-derivatives, with the exception of complex ReL2 (binding affinity: -12.62 kcal/mol), showed higher binding affinities than the reference drug chloroquine (CQ, -13.56 kcal/mol). Furthermore, the ligands exhibited superior binding affinity relative to their corresponding Re(I) complexes, which is reflected in their antiplasmodial activity.

The role of substituted pyridine Schiff bases as ancillary ligands in the optical properties of a new series of fac-rhenium(i) tricarbonyl complexes: a theoretical view

Over the last few years, luminescent Re(i) tricarbonyl complexes have been increasingly proposed as fluorophores suitable for fluorescence microscopy to visualize biological structures and cells. In this sense, incorporating an asymmetrical pyridine Schiff base (PSB) as the ancillary ligand strongly modifies the staining and luminescent properties of Re(i) tricarbonyl complexes. In this work, we analyzed two series of Re(i) tricarbonyl complexes with their respective PSB ligands: (1) fac-[Re(CO)3(2,2'-bpy)(PSB)]1+ and (2) fac-[Re(CO)3(4,4'-bis(ethoxycarbonyl)-2,2'-bpy)(PSB)]1+, where the PSB exhibits substitutions at positions 4 or 6 in the phenolic ring with methyl or halogen substituents. Thus, we performed computational relativistic DFT and TDDFT studies to determine their optical properties. The ten complexes analyzed showed absorption in the visible light range. Furthermore, our analyses, including zero-field splitting (ZFS), allowed us to determine that the low-lying excited state locates below the 3LLCT states. Interestingly, seven of the ten analyzed complexes, whose corresponding PSB harbors an intramolecular hydrogen bond (IHB), exhibited luminescent emission that could be suitable for biological purposes: large Stokes shift, emission in the range 600-700 nm and τ in the order of 10-2 to 10-3 s. Conversely, the three complexes lacking the IHB due to two halogen substituents in the corresponding PSB showed a predicted emission with the lowest triplet excited state energy entering the NIR region. The main differences in the complexes' photophysical behavior have been explained by the energy gap law and time-resolved luminescence. These results emphasize the importance of choosing suitable substituents at the 4 and 6 positions in the phenolic ring of the PSB, which determine the presence of the IHB since they modulate the luminescence properties of the Re(i) core. Therefore, this study could predict Re(i) tricarbonyl complexes' properties, considering the desired emission features for biological and other applications.

Synthesis, Crystal Structure, Inhibitory Activity and Molecular Docking of Coumarins/Sulfonamides Containing Triazolyl Pyridine Moiety as Potent Selective Carbonic Anhydrase IX and XII Inhibitors

In this work, two classes of Carbonic Anhydrase (CA) inhibitors, sulfonamide and coumarin derivatives linked to pyta moiety (2a-b) and their corresponding rhenium complexes (3a-b), were designed. These compounds were synthesized and fully characterized by classical analytical methods and X-ray diffraction. All the synthesized compounds were evaluated for their inhibitory activity against the hCA isoforms I, II, IX and XII. They exhibited high inhibitory activities in the range of nanomolar for both hCA IX and hCA XII isoforms. The sulfonamide compound 2a showed the strongest inhibition against the tumour-associated hCA IX isoform with a Ki of 11.7 nM. The tumour-associated isoforms hCA IX and hCA XII were selectively inhibited by all the coumarin derivatives, with inhibition constants ranging from 12.7 nM (2b) to 44.5 nM (3b), while the hCA I and II isoforms were slightly inhibited (in the micromolar range), as expected. In terms of selectivity, compared to previously published rhenium complex-based CA inhibitors, complex 3b showed one of the highest selectivities against hCA IX and hCA XII compared to the off-target isoforms hCA I and hCA II, making it a potential anti-cancer drug candidate. Molecular docking calculations were performed to investigate the inhibition profiles of the investigated compounds at the tumour-associated hCA IX active site and to rationalize our results.

The crystal structure of fac-tricarbonyl (N′-benzoyl-N,N-diphenylcarbamimidothioato-κ2 S,O)-(pyrazole-κN)rhenium(I) — methanol (1/1) C26H23O4N4SRe

C26H23O4N4SRe, triclinic, P 1 ‾ $\bar{1}$ (no. 2), a = 9.919(2) Å, b = 11.752(3) Å, c = 12.717(3) Å, α = 111.098(7)°, β = 94.467(7)°, γ = 98.295(7)°, V = 1354.9(5) Å3, Z = 2, Rgt (F) = 0.0342, wRref (F 2) = 0.0843, T = 102.0(2) K.

Review on 99mTc radiopharmaceuticals with emphasis on new advancements

Rapid imaging acquisition, high spatial resolution and sensitivity, powered by advancements in solid-state detector technology, are significantly changing the perspective of single photon emission tomography (SPECT). In particular, this evolutionary step is fueling a rediscovery of technetium-99m, a still unique radionuclide within the nuclear medicine scenario because of its ideal nuclear properties and easy preparation of its radiopharmaceuticals that does not require a costly infrastructure and complex procedures. Scope of this review is to show that the arsenal of technetium-99m radiopharmaceuticals is already equipped with imaging agents that may complement and integrate the role played by analogous tracers developed for positron emission tomography (PET). These include, in particular, somatostatin (SST) and prostate-specific membrane antigen (PSMA) receptor targeting agents, and a number of peptide-derived radiopharmaceuticals. Additionally, these recent technological developments, combined with new myocardial perfusion tracers having more favorable biodistribution and pharmacokinetic properties as compared to current commercial agents, may also reinvigorate the prevailing position still hold by technetium-99m radiopharmaceuticals in nuclear cardiology.

Photophysical and Electrocatalytic Properties of Rhenium(I) Triazole-Based Complexes

A series of [Re(N^N)(CO)3(Cl)] (N^N = diimine) complexes based on 4-(pyrid-2-yl)-1,2,3-triazole (1), 1-benzyl-4-(pyrimidin-2-yl)-1,2,3-triazole (2), and 1-benzyl-4-(pyrazin-2-yl)-1,2,3-triazole (3) diimine ligands were prepared and their photophysical and electrochemical properties were characterized. The ligand-based reduction wave is shown to be highly sensitive to the nature of the triazole-based ligand, with the peak potential shifting by up to 600 mV toward more positive potential from 1 to 3. All three complexes are phosphorescent in solution at room temperature with λmax ranging from 540 nm (1) to 638 nm (3). Interestingly, the complexes appear to show inverted energy-gap law behaviour (τ = 43 ns for 1 versus 92 ns for 3), which is tentatively interpreted as reduced thermal accessibility of metal-centred (3MC) states from photoexcited metal to ligand charge transfer (3MLCT) states upon stabilisation of the N^N-centred lowest unoccupied molecular orbital (LUMO). The photophysical characterisation, supported by computational data, demonstrated a progressive stabilization of the LUMO from complex 1 to 3, which results in a narrowing of the HOMO–LUMO energy gap (HOMO = highest occupied molecular orbital) across the series and, correspondingly, red-shifted electronic absorption and photoluminescence spectra. The two complexes bearing pyridyl (1) and pyrimidyl (2) moieties, respectively, showed a modest ability to catalyse the electroreduction of CO2, with a peak potential at ca. −2.3 V versus Fc/Fc+. The catalytic wave that is observed in the cyclic voltammograms is slightly enhanced by the addition of water as a proton source.